S8876
磺胺甲基嘧啶
ReagentPlus®, ≥99.0%
别名:
4-氨基-N-(4-甲基-2-嘧啶基)苯磺酰胺, N1-(4-甲基嘧啶-2-基)磺胺
质量水平
产品线
ReagentPlus®
方案
≥99.0%
SMILES字符串
Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1
InChI
1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)
InChI key
QPPBRPIAZZHUNT-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
法律信息
ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Xian Zhang et al.
Environmental science and pollution research international, 19(5), 1392-1404 (2012-06-30)
Estrogenic compounds and antibiotic residues in environment are receiving significant attention because of their potential adverse effects on ecosystems and human health. The objectives of this study were to determine the occurrence and seasonal variability of eight kinds of estrogenic
Jia Pan et al.
Chemical communications (Cambridge, England), 47(1), 352-354 (2010-08-24)
A phosphine-mediated one-step disulfide formation from S-nitrosothiols has been developed. This reaction can convert unstable S-nitrosothiols to stable disulfides via sulfenamide intermediates under very mild conditions. It has the potential to be used for the detection of S-nitrosothiols.
Regioselective hydroxysulfenylation of alpha,beta-unsaturated imines: enhanced stability of an intermediate radical.
Masafumi Ueda et al.
Angewandte Chemie (International ed. in English), 47(30), 5600-5604 (2008-06-17)
Kristiina M Huttunen et al.
Journal of medicinal chemistry, 52(14), 4142-4148 (2009-06-16)
Metformin is a potent antidiabetic agent and currently used as a first-line treatment for patients with type 2 diabetes. Unfortunately, the moderate absorption and uncomfortable gastrointestinal adverse effects associated with metformin therapy impair its use. In this study, two novel
Zhanhui Wang et al.
Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment, 25(5), 574-582 (2008-05-14)
A new monoclonal antibody (Mab) against sulphamerazine (SMR) was produced and a fluorescence polarisation immunoassay (FPIA) based on the Mab was developed and optimized for the simultaneous qualitative screening of SMR, sulphamethazine (SMZ) and sulphadiazine (SDZ). The Mab, raised from
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持